ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: interstitial lung disease

Anti-SAE Identifies a Subtype of Dermatomyositis

  |  

Albayda et al. describes a North American cohort of patients with dermatomyositis, reporting that small ubiquitin-like modifier activating enzyme (SAE) autoantibodies are clearly associated with this clinical disease. Patients with this clinical phenotype most commonly present with a rash first, followed by muscle involvement.

New Africa / shutterstock.com

A Rheumatologist & Pulmonologist Discuss RA-ILD

Joshua Solomon, MD, & Paul F. Dellaripa, MD  |  

Introduction The understanding and treatment of rheuma­toid arthritis (RA) has evolved dramatically in the past 20 years. As gains have been made in treating joint disease in RA, our understanding of the impact of extra-articular manifestations of RA, such as cardiac and lung disease—specifically interstitial lung disease (ILD)—has gradually increased. While rheumatologists increasingly appreciate the…

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care

Sarah D. Bayefsky, MD, Kimberly DeQuattro, MD, & Rebecca E. Sadun, MD, PhD  |  

Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and…

2 Cases of SLE-Associated Diffuse Alveolar Hemorrage

2 Cases of SLE-Associated Diffuse Alveolar Hemorrhage

Abhimanyu Amarnani, MD, PhD, Nicole K. Zagelbaum Ward, DO, MPH, Lauren Mathias, MD, Nathan Lim, MD, Baljeet Rai, MD, Sky Wang, MD, & William Stohl, MD, PhD  |  

Pulmonary manifestations in patients with systemic lupus erythematosus (SLE) include pleuritis, acute pneumonitis, interstitial lung disease, pulmonary arterial hypertension, shrinking lung syndrome and diffuse alveolar hemorrhage (DAH). DAH is a rare, but devastating, complication of SLE, with high mortality rates. The incidence of DAH in SLE ranges from 0.6% to 5.4%, but the mortality rate…

3 Educators Offer Lessons Learned on Rheumatology Training

Leslie Kahl, MD, Sheryl Mascarenhas, MD, & Rachel M. Wolfe, MD  |  

Leslie Kahl, MD, on Coaching I have been an academic clinician-educator for my entire career and, like most of my colleagues, have been called upon to advise, mentor and coach countless trainees and junior faculty members. Unlike most clinician-educators, though, I also served as associate dean for student affairs at Washington University School of Medicine,…

Rituximab Seems Safe & Effective for Systemic Sclerosis

Marilynn Larkin  |  

NEW YORK (Reuters Health)—Rituximab seemed to be a safe and effective treatment for systemic sclerosis (SSc) in a placebo-controlled validation trial in Japan.1 “A number of studies have examined B-cell depletion therapy for systemic sclerosis, and many of them have suggested that [this] is effective in treating systemic sclerosis,” Ayumi Yoshizaki, MD, tells Reuters Health…

Case Report: Digital Ulcers & Weight Loss in a Pediatric Patient

Anusha Vuppala, MD, & Sarwat Umer, MD  |  

Juvenile dermatomyositis (JDM) is a childhood form of inflammatory myopathy affecting children younger than 18 years. The diagnosis of JDM is based on characteristic clinical features of proximal muscle weakness, skin rash, elevated muscle enzymes, magnetic resonance imaging and muscle biopsy.1 Autoantibodies seen in patients with inflammatory myopathy are not only associated with particular phenotypes…